Inozyme Pharma Statistics Share Statistics Inozyme Pharma has 64.56M
shares outstanding. The number of shares has increased by 2.91%
in one year.
Shares Outstanding 64.56M Shares Change (YoY) 2.91% Shares Change (QoQ) 0.5% Owned by Institutions (%) 67.33% Shares Floating 43.37M Failed to Deliver (FTD) Shares 49,353 FTD / Avg. Volume 2.19%
Short Selling Information The latest short interest is 1.52M, so 0% of the outstanding
shares have been sold short.
Short Interest 1.52M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1.21
Valuation Ratios The PE ratio is -1.71 and the forward
PE ratio is -3.33.
Inozyme Pharma's PEG ratio is
-0.09.
PE Ratio -1.71 Forward PE -3.33 PS Ratio 0 Forward PS 244.3 PB Ratio 3.01 P/FCF Ratio -1.89 PEG Ratio -0.09
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Inozyme Pharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.56,
with a Debt / Equity ratio of 0.81.
Current Ratio 3.56 Quick Ratio 3.56 Debt / Equity 0.81 Debt / EBITDA -0.45 Debt / FCF -0.51 Interest Coverage 18.72
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.52M Employee Count 67 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -7.83% in the
last 52 weeks. The beta is 2.29, so Inozyme Pharma's
price volatility has been higher than the market average.
Beta 2.29 52-Week Price Change -7.83% 50-Day Moving Average 2.98 200-Day Moving Average 2.77 Relative Strength Index (RSI) 82.66 Average Volume (20 Days) 2,255,013
Income Statement
Revenue n/a Gross Profit n/a Operating Income -104.03M Net Income -102.02M EBITDA -104.03M EBIT -107.58M Earnings Per Share (EPS) -1.62
Full Income Statement Balance Sheet The company has 21.08M in cash and 46.87M in
debt, giving a net cash position of -25.79M.
Cash & Cash Equivalents 21.08M Total Debt 46.87M Net Cash -25.79M Retained Earnings -387.95M Total Assets 95.16M Working Capital 50.86M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -91.91M
and capital expenditures -62K, giving a free cash flow of -91.97M.
Operating Cash Flow -91.91M Capital Expenditures -62K Free Cash Flow -91.97M FCF Per Share -1.46
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
